You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Anticancer effects of Coumarin Sulfonamides
Edit
This entry is adapted from the peer-reviewed paper 10.3390/molecules27051604

Coumarin is an important six-membered aromatic heterocyclic pharmacophore, widely distributed in natural products and synthetic molecules. The versatile and unique features of coumarin nucleus, in combination with privileged sulfonamide moiety, have enhanced the broad spectrum of biological activities. The research and development of coumarin, sulfonamide-based pharmacology, and medicinal chemistry have become active topics, and attracted the attention of medicinal chemists, pharmacists, and synthetic chemists. Coumarin sulfonamide compounds and analogs as clinical drugs have been used to cure various diseases with high therapeutic potency, which have shown their enormous development value. The diversified and wide array of biological activities such as anticancer, antibacterial, anti-fungal, antioxidant and anti-viral, etc. were displayed by diversified coumarin sulfonamides.

coumarin sulfonamide anticancer agents

1. Introduction

Ever since the first time that coumarin 1 was isolated from natural source tonka bean (Dipteryx odorata), commonly known as cumaru, in 1820 by Vogel [1][2]. Coumarin is an old, important, and diversified oxygen containing six membered heterocyclic classes of 1,2 benzopyrones, which naturally occur in plants and many other species, such as fungi (Armillariella tabescens, Fomitopsis officinalis) and bacteria (Streptomyces niveus, Escherichia coli) [3][4]. More than 1300 coumarins are present in plants, which play vital role in physiology and overall functioning of plants [1]. The general structure of coumarin 1 is given below (Figure 1). In the mid-nineteenth century, the research and development of coumarin-based compounds and hybrid structures began via the famous Perkin condensation reaction between acetic anhydride and salicylaldehyde. The different synthetic classical techniques, such as Knoevenagel, Perkin and Pechmann reactions, are applied to achieve simple coumarins [5][6][7]. The rapid developments in the synthetic chemistry of coumarins have been made, due to their wide therapeutic potential as medicinal drugs. The coumarin scaffolds displayed an array of biological activities, such as coumarin chalcone derivatives, coumarin aryl sulfonamides, and coumarin hydrazine–hydrazone hybrids, etc., which were screened to investigate their anticancer activities [8][9][10][11][12]. Coumarin scaffolds are extensively studied for their antioxidant [13][14][15][16], antibacterial [17][18][19][20], anti-fungal [21][22][23], anti-inflammatory [24][25], anti-diabetic [26], vasorelaxant [27], analgesic [28], anti-HIV [29], antimicrobial [30], anti-coagulation [31], and anti-pyretic [32] activities, etc.
Molecules 27 01604 g001 550
Figure 1. Structure of coumarin 1.

2. Coumarin Sulfonamides as Anti-Cancer Agents and Carbonic Anhydrase Inhibitors

Cancer is one of the most lethal, notable complex and serious threats to human health, and has attracted attention worldwide. All over the world, about 7.6 million people die due to cancer every year, and around 13 million people will likely die before 2030. In 2020, globally, almost 10 million people died due to cancer [33][34]. Extensive research and development work have been conducted in the field of oncology to develop anticancer therapeutic agents, and large breakthroughs and great strides have been made over past 60 years [35]. Coumarin sulfonamide derivatives and analogs have therapeutic potential against different types of cancer cell lines and CAs (carbonic anhydrases). CAs are also known as carbonate dehydratases [36]. CAs are metalloenzymes which are present in all life forms, and are essential for equilibria between different simple but significant reaction species, such as carbon dioxide, proton, and bicarbonate [37][38][39][40][41]. In 1933, 88 years ago, these enzymes were discovered, and are still an extraordinary example of convergent evolution, and extensively studied and investigated for biomedical inhibitory activities. CAs were found in bacteria, archaea and eukarya; genetically, at least eight (α-, β-, γ-, δ-, ζ-, η-, θ- and ι-CAs) distinct families [37][38][39][40][41][42]. The α-CAs family is present in vertebrates, and the bacteria, algae, and cytoplasm of green plants, while β-CAs are found in bacteria, the chloroplasts of monodicotyledons and dicotyledons, and algae. The γ-CAs are mainly present in archaea and some bacteria, the δ-, ζ- and θ-CAs are present in some marine diatoms, and the η-CAs are present in protozoa. The ι-CAs were discovered in marine phytoplankton, as well as in some bacteria [42][43][44][45][46][47][48][49][50][51][52]. There are five membrane-bound isozymes: CA-IV, CA-IX, CA-XII, CA-XIV, and CA-XV), five cytosolic forms CA-I, CA-II, CA-III, CA-VII, and CA-XIII, a secreted CA isozyme CA-VI, and two mitochondrial forms, CA-VA and CA-VB [53][54][55][56][57]. CAs inhibition mechanism with coumarins was unraveled with kinetic and X-ray crystallographic techniques. The first natural product, coumarin, was bound to human isoform hCA-II, but the formation of the enzyme inhibitor complex is not a rapid process, it takes 6 h for incubation period, while other classes take just 15 min for the incubation period [58][59][60][61][62][63]. The coumarin sulfonamides’ anticancer and CAs inhibition activities are discussed below in more detail.

2.1. Benzenesulfonamide-Based Coumarins as Carbonic Anhydrases II and IX Inhibitors

Wang and coworkers designed a solvent-free green methodology to synthesize substituted coumarin containing sulfonamides derivatives, and screened for carbonic anhydrase inhibitory activities. In this synthetic strategy, Meldrum’s acid was reacted with various substituted phenol 5 to achieve substituted malonic acid-based mono phenol esters 6 in (91–94%) yield, which further cyclized with Eaton’s reagent under mild conditions to yield 4-hydroxycoumarin 7 in (79–91%) yield. In the next step, substituted 3-formyl-4-chlorocoumarin 8 (59–73%) was obtained by Vilsmeiere Haack reactions in dimethylformamide (DMF) and phosphoryl chloride. Derivative 8 was treated with substituted sulfonamides in ethanol at room temperature (rt) to 50 °C, leading to the formation of final coumarin sulfonamide derivative 9 in (45–79%) yield (Scheme 1) [64].
Molecules 27 01604 sch001 550
Scheme 1. Synthesis of coumarin containing sulfonamide derivative 9.
The benzenesulfonamide coumarins’ eighteen derivatives were afforded and screened for their in vitro anticancer activity against mouse melanoma cells (B16–F10) and breast carcinoma cell lines (MCF-7), and two human carbonic anhydrase against hCAs II (cytosolic off target isoform) and hCAs IX (trans-membrane tumor-associated isoform). The IC50 calculations were done by using Origin 8.6 software using an inhibitory model with the sum of squares of the residuals minimized. The most active derivative was substituted dimethyl pyrimidine-based coumarin benzene sulfonamide 9a (Figure 2), which displayed the highest and remarkable significant anticancer potential against MCF-7 cell lines with IC50 0.0088 µM when compared with the reference drugs doxorubicin IC50 0.072 µM and semaxanib IC50 0.012 µM. Both the virtual screening and anticancer activity results for MCF-7 showed that the over-expressed CA might be the most active therapeutic candidate that coumarin sulfonamides interacted with. The substituted pyrimidine-based coumarin benzene sulfonamide 9b (Figure 2) and di-tert-butyl substituted coumarin benzenesulfonamide containing pyrimidine 9c (Figure 2) displayed strong inhibition against hCAs II and hCAs IX isoforms with IC50 values of 0.063 µM and 0.124 µM (Table 1) respectively, when compared with standard drugs acetazolamide (AAZ) and sulfanilamide (SA). The SAR studies investigated that the introduction of thiazole and methyl pyrimidine substitutions in the benzenesulfonyl ring of the coumarin enhanced the anticancer and carbonic anhydrase inhibition activities of the below-mentioned coumarin derivatives [64].
Molecules 27 01604 g003 550
Figure 2. Structure of the most active anticancer and CA inhibitors coumarin sulfonamides 9a–9c.
Table 1. Anticancer data of compound 9a and CAs inhibition data of compounds 9b and 9c.
Table
Compound MCF-7 µM Compounds hCAs II µM hCAs IX µM
9a 0.0088 9b - 0.124
Doxorubicin 0.065 9c 0.063 -
Semaxanib 0.0031 AAZ 0.016 0.028
- - SA 0.26 0.29

2.2. Thiazole-Sulfonamide Coumarin Hybrids as hCA I and hCA II Inhibitors

Kurt and colleagues developed a solvent-free approach to achieve the unsubstituted thiazole-based coumarin sulfonamides 17 by the reaction of 2-hydroxybenzaldehyde 10, L-proline and ethyl 3-oxobutanoate 11, by heating for 0.5 h at a temperature of 80–90 °C to obtain 3-acetylcoumarin 12 in 92% yield, which further refluxed for 15 min in chloroform and bromine solutions to obtain 3-(bromoacetyl) coumarin 13 in 98% yield. Refluxing compound 13 with thiourea 14 in ethanol for 1 h gives 2-amino coumarin thiazolyl derivatives 15 (90% yield) that were further treated with benzenesulfonyl chloride 16 derivatives at 60 °C in pyridine, which led to the synthesis of thiazole-based coumarin sulfonamides 17 in 68–82% yield (Scheme 2) [65].
Molecules 27 01604 sch002 550
Scheme 2. Solvent-free synthesis of coumarin sulfonamide derivatives 17.
The thiazole ring of acetazolamide was combined with coumarin moiety to afford biologically active, substituted benzenesulfonamide-based coumaryl thiazole hybrids, and was screened for its anticancer activity against hCA I and hCA II (human carbonic anhydrase isoforms). Among all these compounds, the scaffold coumarin-thiazole-based naphthalene-2-sulpho-namide 17a (Figure 3) displayed the strongest inhibition against hCA I and hCA II with the IC50 values 5.63 µM and 8.48 µM (Table 2), respectively. The SAR showed that bulky substituents such as s tert-butyl, naphthalene and iodine increase inhibitory activity, so compound 17a showed the most potent inhibitory activity due to the steric effect of bulky group substitution, such as naphthalene on sulfonyl group against hCA I and hCA II [65].
Molecules 27 01604 g004 550
Figure 3. Structures of the most active antioxidant and CA inhibitors coumarin sulfonamides 17a.
Table 2. CAs inhibition data and antioxidant data of compounds 17a–17b.
Table
Compound hCA I
IC50 (µM)		 hCA II
IC50 (µM)
17a 5.63 8.48

2.3. Sulfonyl Ureido Coumarins Hybrids as Carbonic Anhydrase Inhibitors

Bozdag and collogues described a single step reaction to afford substituted sulfonyl ureido coumarins 20 in 53–88% yield by the treatment of coumarin 18 and sulfonyl ureido isocyanates 19 in acetonitrile (ACN) or dry acetone (Scheme 3) [66].
Molecules 27 01604 sch003 550
Scheme 3. Synthesis of substituted sulfonyl ureido coumarins 20.
The ary lsulfonylureido coumarin derivatives were evaluated for their inhibitory activity against hCA I and II (carbonic anhydrase cytosolic inhibitor) and hCA IX and XII (tumor-associated isoforms). The 4-chloro-substituted coumarin benzenesulfonamide 20a (Figure 4) exhibited the highest inhibitory activity with a KI value 20.2 nM against hCA IX and 6.0 nM against hCA XII (Table 3). Acetazolamide (AAZ) was used as a standard reference drug with KI = 25.0 nM and KI = 5.7 nM (Table 3) against hCA IX and hCA XII, respectively. The SAR showed that analogue 20a was the most potent due to the presence of electron withdrawing Cl atom in the benzene ring of the sulfonyl ureido group [66].
Molecules 27 01604 g005 550
Figure 4. Structures of the most active coumarin sulfonamide CA inhibitor 20a.
Table 3. CAs inhibition data compound 20a.
Table
Compound hCA IX
KI (nM)		 hCA XII
KI (nM)
20a 20.2 6.0
AAZ 25.0 5.7

2.4. Benzene Sulfonamido-Coumarinyl Hydrazones Hybrids as CA Inhibitors

Chandak et al., in 2016, synthesized sulfonamide bearing coumarin derivatives by a Hantzsch thiazole synthetic approach as shown in Scheme 4. In this synthetic strategy, the thiazoyl hydrazine methylidene pyrazole 31 derivatives were achieved from 4-hydrazinobenzenesulfonamide hydrochloride, further converted into pyrazole-based carbaldehyde bearing thiosemicarbazones, and finally reacted to substituted bromoacetyl-based coumarins 30 by condensation reaction. In the second step, different 6-substituted 3-bromoacetylcoumarins 30 and 4-thioureido-benzenesulfonamide achieved 2-amino-substituted-coumarinylthiazoles 32 by condensation reaction. In the next step, heterocyclic series 33 containing three IBTs prepared by treatment of 2-aminobenzothiazole-6-sulfonamide that first obtained from sulfanilamide and 6-substituted-3-bromoacetylcoumarins. On the other hand, the derivatives of series 4, different 3-acetylcoumarins 29 and 4-hydrazinobenzenesulfonamide hydrochloride 34 by refluxing together in aqueous ethanol with anhydrous sodium acetate, give benzenesulfonamido-coumarinyl hydrazones, 35 (Scheme 4) [67].
Molecules 27 01604 sch004 550
Scheme 4. Synthesis of sulfonamide bearing coumarin derivatives 31–35.
The following sulfonamide-bearing coumarin scaffold consisted of twenty-four compounds evaluated for the inhibition of hCA I, II, IX and XII (human carbonic anhydrase isoforms). Among all of these, the 32a compound (Figure 5) exhibited strong potent inhibitory activity with a KI value 2.28 nM (Table 4) against hCA IX, as compared to standard compound AZA with a KI range 25.0 nM. Moreover, analogues 32a and 32b were most potent with KI values 0.54 nM against hCA XII when compared to AZA with a KI value 5.7 nM. The hybrid structure 4-{2-[1-(2-oxo-2H-chromen-3-yl)ethylidene]hydrazino} benzenesulfonamide 35a revealed the highest activity KI = 13.23 nM for hCA II in comparison with reference drug AZA with KI value 12.1 nM. The compound 4-{2-[1-(6-bromo-2-oxo-2H-chromen-3-yl)ethylidene]hydrazino}benzenesulfonamide 35b (Figure 5) screened potent inhibitory activity with a KI value 21.95 nM against hCA I, as compared to standard compound AZA (acetazolamide) with a KI range 250.0 nM (Table 4). The SAR showed that the introduction of bromo and unsubstituted H-atom on coumarin increase the carbonic anhydrase inhibitory activity of derivatives 35a and 35b (Figure 5), while the presence of electron-withdrawing Cl-atom and unsubstituted H-atom on coumarin enhances the inhibitory activity of compounds 32a and 32b [67].
Molecules 27 01604 g006 550
Figure 5. Structures of the most active coumarin sulfonamide CA inhibitors 32a–32b and 35a–35b.
Table 4. Coumarin sulfonamide as CA inhibitors 32a–32b and 35a–35b.
Table
Compound Number hCA I
KI (nM)		 hCA II
KI (nM)		 hCA IX
KI (nM)		 hCA XII
KI (nM)
32a 263.49 21.20 2.28 0.54
32b 349.63 17.46 2.54 0.54
35a 220.13 13.23 58.61 4.4
35b 21.95 1751.72 23.59 0.62
AZA 250.0 12.1 25.0 5.7

References

  1. De Souza, L.G.; Rennã, M.N.; Figueroa-Villar, J.D. Coumarins as cholinesterase inhibitors. A review. Chem. Biol. Interact. 2016, 254, 11–23.
  2. Peng, X.M.; Damu, L.V.; Zhou, C.H. Current developments of coumarin compounds in medicinal chemistry. Curr. Pharm. Des. 2013, 19, 3884–3930.
  3. Kostova, I. Synthetic and natural coumarins as antioxidants. Mini Rev. Med. Chem. 2006, 6, 365–374.
  4. Pereira, M.T.; Franco, P.D.; Vitorio, F.; Kümmerle, E.A. Coumarin compounds in medicinal chemistry: Some important examples from the last years. Curr. Top. Med. Chem. 2018, 18, 124–148.
  5. Murray, R.D.H. Coumarins. Nat. Prod. Rep. 1995, 12, 477–505.
  6. Pereira, T.M.; Vitório, F.; Amaral, R.C.; Zanoni, K.P.S.; Iha, N.Y.M.; Kümmerle, A.E. Microwave-assisted synthesis and photophysical studies of novel fluorescent N-acylhydrazone and semicarbazone-7-OH-coumarin dyes. New J. Chem. 2016, 40, 8846–8854.
  7. Symeonidis, T.; Chamilos, M.; Litina, D.J.H.; Kallitsakis, M.; Litinas, K.E. Synthesis of hydroxycoumarins and hydroxybenzo- or coumarins as lipid peroxidation inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1139–1142.
  8. Sashidhara, K.V.; Kumar, A.; Kumar, J.M.; Sinha, S.S. Synthesis and in vitro evaluation of novel coumarinechalcone hybrids as potential anticancer agents. Bioorg. Med. Chem. Lett. 2010, 20, 7205–7721.
  9. Reddy, N.S.; Mallireddigari, M.R.; Cosenza, S.; Gumireddy, K.; Bell, S.C.; Reddy, E.P.; Reddy, M.R. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg. Med. Chem. Lett. 2004, 14, 4093–4097.
  10. Nasr, S.T.; Bondock, M. Youns, Anticancer activity of new coumarin substituted hydrazide-hydrazone derivatives. Eur. J. Med. Chem. 2014, 76, 539–548.
  11. Thakur, A.; Singla, R.; Jaitak, V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur. J. Med. Chem. 2015, 101, 476–495.
  12. Devji, T.; Reddy, C.; Woo, C.; Awale, S.; Kadota, S.; Carrico-Moniz, D. Pancreatic anticancer activity of a novel geranylgeranylatedcoumarin derivative. Bioorg. Med. Chem. Lett. 2011, 21, 5770–5773.
  13. Alshibl, H.M.; Al-Abdullah, E.S.; Haiba, M.E.; Alkahtani, H.M.; Awad, G.E.A.; Mahmoud, A.H.; Ibrahim, B.M.M.; Bari, A.; Villinger, A. Synthesis and Evaluation of New Coumarin Derivatives as Antioxidant, Antimicrobial, and Anti-Inflammatory Agents. Molecules 2020, 25, 3251.
  14. Melagraki, G.; Afantitis, A.; Igglessi-Markopoulou, O.; Detsi, A.; Koufaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D.J. Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur. J. Med. Chem. 2009, 44, 3020–3026.
  15. Fylaktakidou, K.C.; Hadjipavlou-Litina, D.J.; Litinas, K.E.; Nicolaides, D.N. Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. Curr. Pharm. Des. 2004, 10, 3813–3833.
  16. Kontogiorgis, C.; Hadjipavlou-Litina, D. Biological evaluation of several coumarins derivatives designed as possible anti-inflammatory/antioxidant agents. J. Enzym. Inhib. Med. Chem. 2003, 18, 63–69.
  17. Rehman, S.U.; Chohan, Z.H.; Gulnaz, F.; Supuran, C.T. In-vitro antibacterial, antifungal and cytotoxic activities of some coumarins and their metal complexes. J. Enzym. Inhib. Med. Chem. 2005, 20, 333–340.
  18. Kalluraya, B.; Vishwanatha, P.; Isloor, A.M.; Rai, G.; Kotian, M. Synthesis and biological activity of 6-substituted-3- coumarins. Boll. Chim. Farm. 2000, 139, 263–266.
  19. Musiciki, B.; Periers, A.M.; Laurin, P.; Ferroud, D.; Benedetti, Y.; Lachaud, S.; Chatreaux, F.; Haesslein, J.L.; LLtis, A.; Pierre, C.; et al. Improved antibacterial activities of coumarin antibiotics bearing 5′,5′-dialkylnoviose: Biological activity of RU79115. Bioorg. Med. Chem. Lett. 2000, 10, 1695.
  20. De Souza, S.M.; Monache, F.D.; Smânia, A. Antibacterial activity of coumarins. Z. Nat. C 2005, 60, 693–700.
  21. Guerra, F.Q.S.; de Araújo, R.S.A.; de Sousa, J.P.; de Pereira, F.O.; Mendonça-Junior, F.J.B.; Barbosa-Filho, J.M.; de Oliveira Lima, E. Evaluation of antifungal activity and mode of action of new coumarin derivative, 7-hydroxy-6-nitro-2h-1-benzopyran-2-one, against Aspergillus spp. Evid. Based Complement. Altern. Med. 2015, 2015, 925096.
  22. Montagner, C.; de Souza, S.M.; Groposo, C.; DelleMonache, F.; Smânia, E.F.A.; Smânia, A., Jr. Antifungal activity of coumarins. Z. Nat. C J. Biosci. 2008, 63, 21–28.
  23. Sardari, S.; Mori, Y.; Horita, K.; Micetich, R.G.; Nishibe, S.; Daneshtalab, M. Synthesis and antifungal activity of coumarins and angular furanocoumarins. Bioorg. Med. Chem. 1999, 7, 1933–1940.
  24. Ghate, M.; Manohar, D.; Kulkarni, V.; Shobha, R.; Kattimani, S.Y. Synthesis of vanillin ethers from 4-(bromomethyl) coumarins as anti-inflammatory agents. Eur. J. Med. Chem. 2003, 38, 297–302.
  25. Christos, A.K.; Dimitra, J.H. Synthesis and anti-inflammatory activity of coumarin derivatives. J. Med. Chem. 2005, 48, 6400–6408.
  26. Li, H.; Yao, Y.; Li, L. Coumarins as potential antidiabetic agents. J. Pharm. Pharmacol. 2017, 69, 1253–1264.
  27. Campos-Toimil, M.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 783–786.
  28. Ghate, M.; Kusanur, R.A.; Kulkarni, M.V. Synthesis and in vivo analgesic and anti-inflammatory activity of some bi heterocyclic coumarin derivatives. Eur. J. Med. Chem. 2005, 40, 882–887.
  29. Kostova, I.; Raleva, S.; Genova, P.; Argirova, R. Structure-activity relationships of synthetic coumarins as hiv-1 inhibitors. Bioinorg. Chem. Appl. 2006, 2006, 68274.
  30. Ojala, T.; Remes, S.; Haansuu, P.; Vuorela, H.; Hiltunen, R.; Haatela, K.; Vuorela, P. Antimicrobial activity of some coumarin containing herbal plants growing in Finland. J. Ethnopharmacol. 2000, 73, 299–305.
  31. Abdelhafez, M.O.; Amin, M.K.; Batran, Z.R.; Maher, J.T.; Nada, A.S.; Sethumadhavan, S. Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives. Bioorg. Med. Chem. 2010, 18, 3371–3378.
  32. Ahmad, R.; Asad, M.; Siddiqui, N.Z.; Kumar, A. Evaluation of antipyretic and antinociceptive potential of new heterocyclic derivatives of 3-formyl-4-hydroxycoumarin in rats. J. Pharm. Appl. Sci. 2013, 3, 253–259.
  33. Hassanpour, S.H.; Dehghani, M. Review of cancer from perspective of molecular. J. Cancer Res. Pract. 2017, 4, 127–129.
  34. Arruebo, M.; Vilaboa, N.; Sáez-Gutierrez, B.; Lambea, J.; Tres, A.; Valladares, M.; González-Fernández, Á. Assessment of the evolution of cancer treatment therapies. Cancers 2011, 3, 3279–3330.
  35. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.J.; Lonigro, R.J.; Brenner, J.C.; et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239–243.
  36. Irfan, A.; Rubab, L.; Rehman, U.M.; Anjum, R.; Ullah, S.; Marjana, M.; Qadeer, S.; Sana, S. Coumarin sulfonamide derivatives: An emerging class of therapeutic agents. Heterocycl. Commun. 2020, 26, 46–59.
  37. Supuran, C.T. Structure-based drug discovery of carbonic anhydrase inhibitors. J. Enzym. Inhib. Med. Chem. 2012, 27, 759–772.
  38. Wagner, J.; Avvaru, S.B.; Robbins, H.A.; Scozzafava, A.; Supuran, T.C.; McKenna, R. Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: Solution and crystallographic investigations. Bioorg. Med. Chem. 2010, 18, 4873–4878.
  39. Supuran, C.T. Bacterial carbonic anhydrases as drug targets: Toward novel antibiotics. Front. Pharmacol. 2011, 2, 34.
  40. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011, 10, 767–777.
  41. Supuran, C.T. Carbonic anhydrase inhibitors: An editorial. Expert Opin. Ther. Pat. 2013, 23, 677–679.
  42. Angeli, A.; Carta, F.; Supuran, C.T. Carbonic Anhydrases: Versatile and Useful Biocatalysts in Chemistry and Biochemistry. Catalysts 2020, 10, 1008.
  43. Capasso, C.; Supuran, C.T. An overview of the alpha-, beta- and gamma-carbonic anhydrases from bacteria: Can bacterial carbonic anhydrases shed new light on evolution of bacteria. J. Enzym. Inhib. Med. Chem. 2015, 30, 325–332.
  44. Supuran, C.T.; Capasso, C. The η-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin. Ther. Targets 2015, 19, 551–563.
  45. Del Prete, S.; Vullo, D.; De Luca, V.; Supuran, C.T.; Capasso, C. Biochemical characterization of the δ-carbonic anhydrase from the marine diatom Thalassiosiraweissflogii, TweCA. J. Enzym. Inhib. Med. Chem. 2014, 29, 906–911.
  46. Stefanucci, A.; Angeli, A.; Dimmito, M.P.; Luisi, G.; Del Prete, S.; Capasso, C.; Donald, W.A.; Mollica, A.; Supuran, C.T. Activation of β- and γ-carbonic anhydrases from pathogenic bacteria with tripeptides. J. Enzym. Inhib. Med. Chem. 2018, 33, 945–950.
  47. Angeli, A.; Del Prete, S.; Alasmary, F.A.S.; Alqahtani, L.S.; AlOthman, Z.; Donald, W.A.; Capasso, C.; Supuran, C.T. The first activation studies of the η-carbonic anhydrase from the malaria parasite Plasmodium falciparum with amines and amino acids. Bioorg. Chem. 2018, 80, 94–98.
  48. Angeli, A.; Buonanno, M.; Donald, W.A.; Monti, S.M.; Supuran, C.T. The zinc—But not cadmium—Containing ζ-carbonic from the diatom Thalassiosiraweissflogii is potently activated by amines and amino acids. Bioorg. Chem. 2018, 80, 261–265.
  49. Angeli, A.; Kuuslahti, M.; Parkkila, S.; Supuran, C.T. Activation studies with amines and amino acids of the α-carbonic anhydrase from the pathogenic protozoan Trypanosoma cruzi. Bioorg. Med. Chem. 2018, 26, 4187–4190.
  50. Angeli, A.; Del Prete, S.; Osman, S.M.; Alasmary, F.A.S.; AlOthman, Z.; Donald, W.A.; Capasso, C.; Supuran, C.T. Activation studies with amines and amino acids of the β-carbonic anhydrase encoded by the Rv3273 gene from the pathogenic bacterium Mycobacterium tuberculosis. J. Enzym. Inhib. Med. Chem. 2018, 33, 364–369.
  51. Angeli, A.; Del Prete, S.; Donald, W.A.; Capasso, C.; Supuran, C.T. The γ-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae is potently activated by amines and amino acids. Bioorg. Chem. 2018, 77, 1–5.
  52. Jensen, E.L.; Clement, R.; Kosta, A.; Maberly, S.C.; Gontero, B. A new widespread subclass of carbonic anhydrase in marine phytoplankton. ISME J. 2019, 13, 2094–2106.
  53. Nishimori, I.; Minakuchi, T.; Onishi, S.; Vullo, D.; Cecchi, A.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg. Med. Chem. 2007, 15, 7229–7236.
  54. Köhler, K.; Hillebrecht, A.; Schulze, W.J.; Innocenti, A.; Heine, A.; Supuran, C.T.; Klebe, G. Saccharin inhibits carbonicanhydrases: Possible explanation for its unpleasant metallic aftertaste. Angew. Chem. 2007, 46, 7697–7699.
  55. Supuran, C.T.; Scozzafava, A.; Ilies, M.A.; Briganti, F. Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J. Enzym. Inhib. 2000, 15, 381–401.
  56. Scozzafava, A.; Briganti, F.; Ilies, M.A.; Supuran, C.T. Carbonic anhydrase inhibitors. Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus the cytosolic isozymes. J. Med. Chem. 2000, 43, 292–300.
  57. De Simone, G.; Vitale, R.M.; Di Fiore, A.; Pedone, C.; Scozzafava, A.; Montero, J.L.; Winum, J.Y.; Supuran, C.T. Carbonic anhydrase inhibitors:hypoxia-activatable sulfonamides incorporatingdisulfide bonds that target the tumor-associatedisoform IX. J. Med. Chem. 2006, 49, 5544–5551.
  58. Maresca, A.; Temperini, C.; Vu, H.; Pham, N.B.; Poulsen, S.A.; Scozzafava, A.; Quinn, R.J.; Supuran, C.T. Non-zinc mediated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc. 2009, 131, 3057–3062.
  59. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C.T. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J. Med. Chem. 2010, 53, 335–344.
  60. Supuran, C.T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug. Discov. 2008, 7, 168–181.
  61. Supuran, C.T. Structure and function of carbonic anhydrases. Biochem. J. 2016, 473, 2023–2032.
  62. Nocentini, A.; Supuran, C.T. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin. Drug Discov. 2019, 14, 1175–1197.
  63. Supuran, C.T. Coumarin carbonic anhydrase inhibitors from natural sources. J. Enzym. Inhib. Med. Chem. 2020, 35, 1462–1470.
  64. Wang, Z.C.; Qin, Y.J.; Wang, P.F.; Yang, Y.A.; Wen, Q.; Zhang, X.; Qiu, H.Y.; Duan, Y.T.; Wang, Y.T.; Sang, Y.L.; et al. Sulfonamides containing coumarin moieties selectively and potently inhibit carbonic anhydrases II and IX: Design, synthesis, inhibitory activity and 3D-QSAR analysis. Eur. J. Med. Chem. 2013, 66, 1–11.
  65. Kurt, B.Z.; Sonmez, F.; Bilen, C.; Ergun, A.; Gencer, N.; Arslan, O.; Kucukislamoglu, M. Synthesis, antioxidant and carbonic anhydrase I and II inhibitory activities of novel sulphonamide-substituted coumarylthiazole derivatives. J. Enzym. Inhib. Med. Chem. 2016, 31, 78–89.
  66. Bozdag, M.; Ferraroni, M.; Carta, F.; Vullo, D.; Lucarini, L.; Orlandini, E.; Rossello, A.; Nuti, E.; Scozzafava, A.; Masini, E.; et al. Structural insights on carbonic anhydrase inhibitory action, isoform selectivity, and potency of sulfonamides and coumarins incorporating arylsulfonylureido groups. J. Med. Chem. 2014, 57, 9152–9167.
  67. Chandak, N.; Ceruso, M.; Supuran, C.T.; Sharma, P.K. Novel sulfonamide bearing coumarin scaffolds as selective inhibitors of tumor associated carbonic anhydrase isoforms IX and XII. Bioorg. Med. Chem. 2016, 24, 2882–2886.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemical Research Methods
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mariusz Mojzych
View Times: 1.4K
Entry Collection: Organic Synthesis
Revisions: 2 times (View History)
Update Date: 22 Mar 2022
Table of Contents
Academic Video Service
Feedback